Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Rosenthal
S H
SH
Fenton
M L
ML
Harnett
D S
DS
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002230:Carbidopa / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000523:psychology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D011605:Psychoses, Substance-Induced / Q000188:drug therapy* / Q000523:psychology
D000978:Antiparkinson Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D003024:Clozapine; D002230:Carbidopa